Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single‐blind placebo‐controlled study

Preeshila Behary; Haya Alessmii; Alexander D Miras; George Tharakan; Kleopatra Alexiadou; Madhawi M. Aldhwayan; Sanjay Purkayastha; Krishna Moorthy; Ahmed R Ahmed; Stephen R Bloom FRS; Tricia M Tan

doi:10.1111/dom.15028

Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single‐blind placebo‐controlled study

Preeshila Behary, Haya Alessmii, Alexander D Miras, George Tharakan, Kleopatra Alexiadou, Madhawi M. Aldhwayan, Sanjay Purkayastha, Krishna Moorthy, Ahmed R Ahmed, Stephen R Bloom FRS, Tricia M Tan

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

112 Downloads (Pure)

Abstract

Aims: To investigate whether the elevation in postprandial concentrations of the gut hormones glucagon‐like peptide‐1 (GLP‐1), oxyntomodulin (OXM) and peptide YY (PYY) accounts for the beneficial changes in food preferences, sweet taste function and eating behaviour after Roux‐en‐Y gastric bypass (RYGB). Materials and methods: This was a secondary analysis of a randomized single‐blind study in which we infused GLP‐1, OXM, PYY (GOP) or 0.9% saline subcutaneously for 4 weeks in 24 subjects with obesity and prediabetes/diabetes, to replicate their peak postprandial concentrations, as measured at 1 month in a matched RYGB cohort (ClinicalTrials.gov NCT01945840). A 4‐day food diary and validated eating behaviour questionnaires were completed. Sweet taste detection was measured using the method of constant stimuli. Correct sucrose identification (corrected hit rates) was recorded, and sweet taste detection thresholds (EC50s: half maximum effective concencration values) were derived from concentration curves. The intensity and consummatory reward value of sweet taste were assessed using the generalized Labelled Magnitude Scale. Results: Mean daily energy intake was reduced by 27% with GOP but no significant changes in food preferences were observed, whereas a reduction in fat and increase in protein intake were seen post‐RYGB. There was no change in corrected hit rates or detection thresholds for sucrose detection following GOP infusion. Additionally, GOP did not alter the intensity or consummatory reward value of sweet taste. A significant reduction in restraint eating, comparable to the RYGB group was observed with GOP. Conclusion: The elevation in plasma GOP concentrations after RYGB is unlikely to mediate changes in food preferences and sweet taste function after surgery but may promote restraint eating.

Original language	English
Pages (from-to)	1731-1739
Number of pages	9
Journal	Diabetes, Obesity and Metabolism
Volume	25
Issue number	6
Early online date	22 Feb 2023
DOIs	https://doi.org/10.1111/dom.15028
Publication status	Published (in print/issue) - 1 Jun 2023

Bibliographical note

Funding Information:
The authors are grateful to the staff at the Imperial Weight Centre and the Imperial National Institutes of Health Research (NIHR) Clinical Research Facility for their support of this study. The research study was funded by the UK Medical Research Council (MRC) Experimental Medicine Challenge Grant (MR/K02115X/1). The Section of Investigative Medicine is funded by grants from the MRC and Biotechnology and Biological Sciences Research Council and is supported by the NIHR Imperial Biomedical Research Centre Funding Scheme. The research study was also supported by the Imperial NIHR Clinical Research Facility at Imperial College Healthcare NHS Trust. Stephen R. Bloom and Tricia M. Tan are funded by the MRC and by the NIHR. Alexander Miras has been funded with grants from the NIHR, MRC, the JON Moulton Charity Trust, Fractyl and Randox.

Funding Information:
U.K. Medical Research Council (MRC) Experimental Medicine Challenge Grant, Grant/Award Number: MR/K02115X/1 Funding information

Funding Information:
The authors are grateful to the staff at the Imperial Weight Centre and the Imperial National Institutes of Health Research (NIHR) Clinical Research Facility for their support of this study. The research study was funded by the UK Medical Research Council (MRC) Experimental Medicine Challenge Grant (MR/K02115X/1). The Section of Investigative Medicine is funded by grants from the MRC and Biotechnology and Biological Sciences Research Council and is supported by the NIHR Imperial Biomedical Research Centre Funding Scheme. The research study was also supported by the Imperial NIHR Clinical Research Facility at Imperial College Healthcare NHS Trust. Stephen R. Bloom and Tricia M. Tan are funded by the MRC and by the NIHR. Alexander Miras has been funded with grants from the NIHR, MRC, the JON Moulton Charity Trust, Fractyl and Randox. The views expressed are those of the authors and not necessarily those of the funders the UK NHS, the NIHR or the UK Department of Health.

Publisher Copyright:
© 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Keywords

Endocrinology
Internal Medicine
Diabetes and Metabolism
GLP-1
bariatric surgery
weight control
randomized trial
antiobesity drug
obesity therapy
ORIGINAL ARTICLES
GLP‐1
ORIGINAL ARTICLE
Single-Blind Method
Food Preferences
Gastric Bypass/adverse effects
Sucrose
Gastrointestinal Hormones
Glucagon-Like Peptide 1/metabolism
Humans
Peptide YY/metabolism
Prediabetic State/complications
Obesity/complications
Taste
Volunteers

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/dom.15028

Diabetes Obesity Metabolism - 2023 - Behary - Tripeptide gut hormone infusion does not alter food preferences or sweetFinal published version, 648 KBLicence: CC BY-NC

Fingerprint

Dive into the research topics of 'Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single‐blind placebo‐controlled study'. Together they form a unique fingerprint.

Cite this

Behary, P., Alessmii, H., Miras, A. D., Tharakan, G., Alexiadou, K., Aldhwayan, M. M., Purkayastha, S., Moorthy, K., Ahmed, A. R., Bloom FRS, S. R., & Tan, T. M. (2023). Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single‐blind placebo‐controlled study. Diabetes, Obesity and Metabolism, 25(6), 1731-1739. https://doi.org/10.1111/dom.15028

Behary, Preeshila ; Alessmii, Haya ; Miras, Alexander D et al. / Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single‐blind placebo‐controlled study. In: Diabetes, Obesity and Metabolism. 2023 ; Vol. 25, No. 6. pp. 1731-1739.

@article{ee645d4aeedb4043816e91fb6fca3bf1,

title = "Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single‐blind placebo‐controlled study",

abstract = "Aims: To investigate whether the elevation in postprandial concentrations of the gut hormones glucagon‐like peptide‐1 (GLP‐1), oxyntomodulin (OXM) and peptide YY (PYY) accounts for the beneficial changes in food preferences, sweet taste function and eating behaviour after Roux‐en‐Y gastric bypass (RYGB). Materials and methods: This was a secondary analysis of a randomized single‐blind study in which we infused GLP‐1, OXM, PYY (GOP) or 0.9% saline subcutaneously for 4 weeks in 24 subjects with obesity and prediabetes/diabetes, to replicate their peak postprandial concentrations, as measured at 1 month in a matched RYGB cohort (ClinicalTrials.gov NCT01945840). A 4‐day food diary and validated eating behaviour questionnaires were completed. Sweet taste detection was measured using the method of constant stimuli. Correct sucrose identification (corrected hit rates) was recorded, and sweet taste detection thresholds (EC50s: half maximum effective concencration values) were derived from concentration curves. The intensity and consummatory reward value of sweet taste were assessed using the generalized Labelled Magnitude Scale. Results: Mean daily energy intake was reduced by 27% with GOP but no significant changes in food preferences were observed, whereas a reduction in fat and increase in protein intake were seen post‐RYGB. There was no change in corrected hit rates or detection thresholds for sucrose detection following GOP infusion. Additionally, GOP did not alter the intensity or consummatory reward value of sweet taste. A significant reduction in restraint eating, comparable to the RYGB group was observed with GOP. Conclusion: The elevation in plasma GOP concentrations after RYGB is unlikely to mediate changes in food preferences and sweet taste function after surgery but may promote restraint eating.",

keywords = "Endocrinology, Internal Medicine, Diabetes and Metabolism, GLP-1, bariatric surgery, weight control, randomized trial, antiobesity drug, obesity therapy, ORIGINAL ARTICLES, GLP‐1, ORIGINAL ARTICLE, Single-Blind Method, Food Preferences, Gastric Bypass/adverse effects, Sucrose, Gastrointestinal Hormones, Glucagon-Like Peptide 1/metabolism, Humans, Peptide YY/metabolism, Prediabetic State/complications, Obesity/complications, Taste, Volunteers",

author = "Preeshila Behary and Haya Alessmii and Miras, {Alexander D} and George Tharakan and Kleopatra Alexiadou and Aldhwayan, {Madhawi M.} and Sanjay Purkayastha and Krishna Moorthy and Ahmed, {Ahmed R} and {Bloom FRS}, {Stephen R} and Tan, {Tricia M}",

note = "Funding Information: The authors are grateful to the staff at the Imperial Weight Centre and the Imperial National Institutes of Health Research (NIHR) Clinical Research Facility for their support of this study. The research study was funded by the UK Medical Research Council (MRC) Experimental Medicine Challenge Grant (MR/K02115X/1). The Section of Investigative Medicine is funded by grants from the MRC and Biotechnology and Biological Sciences Research Council and is supported by the NIHR Imperial Biomedical Research Centre Funding Scheme. The research study was also supported by the Imperial NIHR Clinical Research Facility at Imperial College Healthcare NHS Trust. Stephen R. Bloom and Tricia M. Tan are funded by the MRC and by the NIHR. Alexander Miras has been funded with grants from the NIHR, MRC, the JON Moulton Charity Trust, Fractyl and Randox. Funding Information: U.K. Medical Research Council (MRC) Experimental Medicine Challenge Grant, Grant/Award Number: MR/K02115X/1 Funding information Funding Information: The authors are grateful to the staff at the Imperial Weight Centre and the Imperial National Institutes of Health Research (NIHR) Clinical Research Facility for their support of this study. The research study was funded by the UK Medical Research Council (MRC) Experimental Medicine Challenge Grant (MR/K02115X/1). The Section of Investigative Medicine is funded by grants from the MRC and Biotechnology and Biological Sciences Research Council and is supported by the NIHR Imperial Biomedical Research Centre Funding Scheme. The research study was also supported by the Imperial NIHR Clinical Research Facility at Imperial College Healthcare NHS Trust. Stephen R. Bloom and Tricia M. Tan are funded by the MRC and by the NIHR. Alexander Miras has been funded with grants from the NIHR, MRC, the JON Moulton Charity Trust, Fractyl and Randox. The views expressed are those of the authors and not necessarily those of the funders the UK NHS, the NIHR or the UK Department of Health. Publisher Copyright: {\textcopyright} 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.",

year = "2023",

month = jun,

day = "1",

doi = "10.1111/dom.15028",

language = "English",

volume = "25",

pages = "1731--1739",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "John Wiley & Sons, Inc.",

number = "6",

}

Behary, P, Alessmii, H, Miras, AD, Tharakan, G, Alexiadou, K, Aldhwayan, MM, Purkayastha, S, Moorthy, K, Ahmed, AR, Bloom FRS, SR & Tan, TM 2023, 'Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single‐blind placebo‐controlled study', Diabetes, Obesity and Metabolism, vol. 25, no. 6, pp. 1731-1739. https://doi.org/10.1111/dom.15028

Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single‐blind placebo‐controlled study. / Behary, Preeshila; Alessmii, Haya; Miras, Alexander D et al.
In: Diabetes, Obesity and Metabolism, Vol. 25, No. 6, 01.06.2023, p. 1731-1739.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single‐blind placebo‐controlled study

AU - Behary, Preeshila

AU - Alessmii, Haya

AU - Miras, Alexander D

AU - Tharakan, George

AU - Alexiadou, Kleopatra

AU - Aldhwayan, Madhawi M.

AU - Purkayastha, Sanjay

AU - Moorthy, Krishna

AU - Ahmed, Ahmed R

AU - Bloom FRS, Stephen R

AU - Tan, Tricia M

N1 - Funding Information: The authors are grateful to the staff at the Imperial Weight Centre and the Imperial National Institutes of Health Research (NIHR) Clinical Research Facility for their support of this study. The research study was funded by the UK Medical Research Council (MRC) Experimental Medicine Challenge Grant (MR/K02115X/1). The Section of Investigative Medicine is funded by grants from the MRC and Biotechnology and Biological Sciences Research Council and is supported by the NIHR Imperial Biomedical Research Centre Funding Scheme. The research study was also supported by the Imperial NIHR Clinical Research Facility at Imperial College Healthcare NHS Trust. Stephen R. Bloom and Tricia M. Tan are funded by the MRC and by the NIHR. Alexander Miras has been funded with grants from the NIHR, MRC, the JON Moulton Charity Trust, Fractyl and Randox. Funding Information: U.K. Medical Research Council (MRC) Experimental Medicine Challenge Grant, Grant/Award Number: MR/K02115X/1 Funding information Funding Information: The authors are grateful to the staff at the Imperial Weight Centre and the Imperial National Institutes of Health Research (NIHR) Clinical Research Facility for their support of this study. The research study was funded by the UK Medical Research Council (MRC) Experimental Medicine Challenge Grant (MR/K02115X/1). The Section of Investigative Medicine is funded by grants from the MRC and Biotechnology and Biological Sciences Research Council and is supported by the NIHR Imperial Biomedical Research Centre Funding Scheme. The research study was also supported by the Imperial NIHR Clinical Research Facility at Imperial College Healthcare NHS Trust. Stephen R. Bloom and Tricia M. Tan are funded by the MRC and by the NIHR. Alexander Miras has been funded with grants from the NIHR, MRC, the JON Moulton Charity Trust, Fractyl and Randox. The views expressed are those of the authors and not necessarily those of the funders the UK NHS, the NIHR or the UK Department of Health. Publisher Copyright: © 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

PY - 2023/6/1

Y1 - 2023/6/1

N2 - Aims: To investigate whether the elevation in postprandial concentrations of the gut hormones glucagon‐like peptide‐1 (GLP‐1), oxyntomodulin (OXM) and peptide YY (PYY) accounts for the beneficial changes in food preferences, sweet taste function and eating behaviour after Roux‐en‐Y gastric bypass (RYGB). Materials and methods: This was a secondary analysis of a randomized single‐blind study in which we infused GLP‐1, OXM, PYY (GOP) or 0.9% saline subcutaneously for 4 weeks in 24 subjects with obesity and prediabetes/diabetes, to replicate their peak postprandial concentrations, as measured at 1 month in a matched RYGB cohort (ClinicalTrials.gov NCT01945840). A 4‐day food diary and validated eating behaviour questionnaires were completed. Sweet taste detection was measured using the method of constant stimuli. Correct sucrose identification (corrected hit rates) was recorded, and sweet taste detection thresholds (EC50s: half maximum effective concencration values) were derived from concentration curves. The intensity and consummatory reward value of sweet taste were assessed using the generalized Labelled Magnitude Scale. Results: Mean daily energy intake was reduced by 27% with GOP but no significant changes in food preferences were observed, whereas a reduction in fat and increase in protein intake were seen post‐RYGB. There was no change in corrected hit rates or detection thresholds for sucrose detection following GOP infusion. Additionally, GOP did not alter the intensity or consummatory reward value of sweet taste. A significant reduction in restraint eating, comparable to the RYGB group was observed with GOP. Conclusion: The elevation in plasma GOP concentrations after RYGB is unlikely to mediate changes in food preferences and sweet taste function after surgery but may promote restraint eating.

AB - Aims: To investigate whether the elevation in postprandial concentrations of the gut hormones glucagon‐like peptide‐1 (GLP‐1), oxyntomodulin (OXM) and peptide YY (PYY) accounts for the beneficial changes in food preferences, sweet taste function and eating behaviour after Roux‐en‐Y gastric bypass (RYGB). Materials and methods: This was a secondary analysis of a randomized single‐blind study in which we infused GLP‐1, OXM, PYY (GOP) or 0.9% saline subcutaneously for 4 weeks in 24 subjects with obesity and prediabetes/diabetes, to replicate their peak postprandial concentrations, as measured at 1 month in a matched RYGB cohort (ClinicalTrials.gov NCT01945840). A 4‐day food diary and validated eating behaviour questionnaires were completed. Sweet taste detection was measured using the method of constant stimuli. Correct sucrose identification (corrected hit rates) was recorded, and sweet taste detection thresholds (EC50s: half maximum effective concencration values) were derived from concentration curves. The intensity and consummatory reward value of sweet taste were assessed using the generalized Labelled Magnitude Scale. Results: Mean daily energy intake was reduced by 27% with GOP but no significant changes in food preferences were observed, whereas a reduction in fat and increase in protein intake were seen post‐RYGB. There was no change in corrected hit rates or detection thresholds for sucrose detection following GOP infusion. Additionally, GOP did not alter the intensity or consummatory reward value of sweet taste. A significant reduction in restraint eating, comparable to the RYGB group was observed with GOP. Conclusion: The elevation in plasma GOP concentrations after RYGB is unlikely to mediate changes in food preferences and sweet taste function after surgery but may promote restraint eating.

KW - Endocrinology

KW - Internal Medicine

KW - Diabetes and Metabolism

KW - GLP-1

KW - bariatric surgery

KW - weight control

KW - randomized trial

KW - antiobesity drug

KW - obesity therapy

KW - ORIGINAL ARTICLES

KW - GLP‐1

KW - ORIGINAL ARTICLE

KW - Single-Blind Method

KW - Food Preferences

KW - Gastric Bypass/adverse effects

KW - Sucrose

KW - Gastrointestinal Hormones

KW - Glucagon-Like Peptide 1/metabolism

KW - Humans

KW - Peptide YY/metabolism

KW - Prediabetic State/complications

KW - Obesity/complications

KW - Taste

KW - Volunteers

UR - https://pure.ulster.ac.uk/en/publications/ee645d4a-eedb-4043-816e-91fb6fca3bf1

UR - http://www.scopus.com/inward/record.url?scp=85150660237&partnerID=8YFLogxK

U2 - 10.1111/dom.15028

DO - 10.1111/dom.15028

M3 - Article

C2 - 36811311

SN - 1462-8902

VL - 25

SP - 1731

EP - 1739

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 6

ER -

Behary P, Alessmii H, Miras AD, Tharakan G, Alexiadou K, Aldhwayan MM et al. Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single‐blind placebo‐controlled study. Diabetes, Obesity and Metabolism. 2023 Jun 1;25(6):1731-1739. Epub 2023 Feb 22. doi: 10.1111/dom.15028

Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single‐blind placebo‐controlled study

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this